Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2704MR)

This product GTTS-WQ2704MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2704MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14904MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1322MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ3269MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ15722MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ1583MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ15712MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ14134MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ4464MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-901608
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW